This year, 45 new drugs with 29 ingredients were listed for reimbursement benefits under Korea’s health insurance.

Among them, the only homegrown new drug was 'Zastaprazan citrate', a P-CAB-based gastroesophageal reflux disease treatment.

As of the 30th, 45 new drugs were listed for reimbursement in Korea’s National health insurance system from January to December 2024, improving patient access.

In January alone, five 5 drugs were reimbursed, including the anti-cancer drugs ‘Braftovi Cap,’ and ‘Bosulif Tab,’ ulcerative colitis treatment ‘Zeposia Cap,’ asthma and COPD treatment ‘Trimbow Inhaler,’ and neurofibromatosis treatment ‘Koselugo Cap.’

In Feb